Mitochondrial dysfunction and type 2 diabetes

Current Diabetes Reports

Volumn 5, Issue 3, 2005, Pages 177-183

  Parish, Rebecca ^b   Petersen, Kitt Falk ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; FATTY ACID; GLUCOSE; GLUCOSE 6 PHOSPHATE; GLYCOGEN; INSULIN RECEPTOR SUBSTRATE 1; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; TRIACYLGLYCEROL; TYROSINE;

ADIPOSE TISSUE; BLOOD GLUCOSE MONITORING; CALORIC INTAKE; CARBON NUCLEAR MAGNETIC RESONANCE; CELL METABOLISM; DIET; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENERGY EXPENDITURE; ENZYME ACTIVITY; EXERCISE; FATTY ACID OXIDATION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; GLYCOGEN MUSCLE LEVEL; GLYCOGENOLYSIS; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID LIVER LEVEL; LIPID METABOLISM; LIPID TRANSPORT; LIPOLYSIS; LIVER METABOLISM; LIVER MITOCHONDRION; METABOLIC SYNDROME X; MITOCHONDRIAL RESPIRATION; MUSCLE METABOLISM; MUSCLE MITOCHONDRION; NON INSULIN DEPENDENT DIABETES MELLITUS; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBESITY; OXYGEN CONSUMPTION; PROTEIN PHOSPHORYLATION; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; WEIGHT REDUCTION; ENERGY METABOLISM; FAT INTAKE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SKELETAL MUSCLE;

DIABETES MELLITUS, TYPE 2; DIETARY FATS; ENERGY METABOLISM; HUMANS; INSULIN RESISTANCE; MITOCHONDRIA, LIVER; MITOCHONDRIA, MUSCLE; MUSCLE, SKELETAL; OBESITY;

EID: 27244434154     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-005-0006-3     Document Type: Review

References (55)

1. Zimmet P, Alberti KG, Shaw J: Global and societal implications of the diabetes epidemic. Nature 2001, 414:782-787.
2. Lillioja S, Mott DM, Howard BV, et al.: Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians. N Engl J Med 1988, 318:1217-1225.
3. Lillioja S, Mott DM, Spraul M, et al.: Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 1993, 329:1988-1992.
4. DeFronzo RA: Pathogenesis of type 2 (non-insulin dependent) diabetes mellitus: a balanced overview. Diabetologia 1992, 35:389-397.
5. Warram JH, Martin BC, Krolewski AS, et al.: Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med 1990, 113:909-915.
6. Azen SP, Peters RK, Berkowitz K, et al.: TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Control Clin Trials 1998, 19:217-231.
7. Shulman GI, Rothman DL, Jue T, et al.: Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. N Engl J Med 1990, 322:223-228.
8. Rothman DL, Shulman RG, Shulman GI: 31P nuclear magnetic resonance measurements of muscle glucose-6-phosphate. Evidence for reduced insulin-dependent muscle glucose transport or phosphorylation activity in non-insulin-dependent diabetes mellitus. J Clin Invest 1992, 89:1069-1075.
9. Rothman DL, Magnusson I, Cline G, et al.: Decreased muscle glucose transport/phosphorylation is an early defect in the pathogenesis of non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci U S A 1995, 92:983-987.
10. Cline GW, Petersen KF, Krssak M, et al.: Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. N Engl J Med 1999, 341:240-246.
11. Boden G, Shulman GI: Free fatty adds in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 2002, 32(suppl 3):14-23.
12. Krssak M, Petersen KF, Dresner A, et al.: Intramyocellular lipid concentrations are correlated with insulin sensitivity in man: a 1H NMR spectroscopy study. Diabetologia 1999, 41:113-116.
13. Roden M, Price TB, Perseghin G, et al.: Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 1996, 97:2859-2865.
14. Petersen KF, Hendler R, Price T, et al.: 13C/31P NMR studies on the mechanism of insulin resistance in obesity. Diabetes 1998, 47:381-386.
15. Dresner A, Laurent D, Marcucci M, et al.: Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 1999, 103:253-259.
16. Griffin ME, Marcucci MJ, Cline GW, et al.: Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes 1999, 48:1270-1274.
17. Yin MJ, Yamamoto Y, Gaynor RB: The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 1998, 396:77-80.
18. Yuan M, Konstantopoulos N, Lee J, et al.: Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001, 293:1673-1677.
19. Kim JK, Kim YJ, Fillmore JJ, et al.: Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 2001, 108:437-446
20. Hundal RS, Petersen KF, Mayerson AB, et al.: Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 2002, 109:1321-1326.
21. Yu C, Chen Y, Cline GW, et al.: Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 2002, 277:50230-50236.
22. Itani SI, Ruderman NB, Schmieder F, Boden G: Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha. Diabetes 2002, 51:2005-2011.
23. Hotamisligil GS, Peraldi P, Budavari A, et al.: IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996, 271:665-668.
24. Bjorntorp P: Abdominal fat distribution and the metabolic syndrome. J Cardiovasc Pharmacol 1992, 20(suppl 8):S26-S28.
25. Foley JE, Thuillez P, Lillioja S, et al.: Insulin sensitivity in adipocytes from subjects with varying degrees of glucose tolerance. Am J Physiol 1986, 251:E306-E310.
26. Saghizadeh M, Ong JM, Garvey WT, et al.: The expression of TNF alpha by human muscle. Relationship to insulin resistance. J Clin Invest 1996, 97:1111-1116.
27. Beisel WR: Herman Award Lecture, 1995: infection-induced malnutrition - from cholera to cytokines. Am J Clin Nutr 1995, 62:813-819.
28. Steppan CM, Lazar MA: Resistin and obesity-associated insulin resistance. Trends Endocrinol Metab 2002, 13:18-23.
29. Fukuhara A, Matsuda M, Nishizawa M, et al.: Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005, 307:426-430.
30. Hug C, Lodish HF: Medicine. Visfatin: a new adipokine. Science 2005, 307:366-367.
31. Moitra J, Mason MM, Olive M, et al.: Life without white fat: a transgenic mouse. Genes Dev 1998, 12:3168-3181.
32. Gavrilova O, Marcus-Samuels B, Graham D, et al.: Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest 2000, 105:271-278.
33. Kim JK, Gavrilova O, Chen Y, et al.: Mechanism of insulin resistance in A-ZIP/F-1 fatless mice. J Biol Chem 2000, 275:8456-8460.
34. Petersen KF, Oral EA, Dufour S, et al.: Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 2002, 109:1345-1350.
35. Conley KE, Jubrias SA, Esselman PC: Oxidative capacity and ageing in human muscle. J Physiol 2000, 526(Pt 1):203-210.
36. Petersen KF, Befroy D, Dufour S, et al.: Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 2003, 300:1140-1142.
37. Michikawa Y, Mazzucchelli F, Bresolin N, et al.: Aging-dependent large accumulation of point mutations in the human mtDNA control region for replication. Science 1999, 286:774-779.
38. Petersen KF, Dufour S, Befroy D, et al.: Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 2004, 350:664-671.
39. Wu Z, Puigserver P, Andersson U, et al.: Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 1999, 98:115-124.
40. Lin J, Wu H, Tarr PT, et al.: Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature 2002, 418:797-801.
41. Zong H, Ren JM, Young LH, et al.: AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. Proc Natl Acad Sci U S A 2002, 99:15983-15987.
42. Wu H, Kanatous SB, Thurmond FA, et al.: Regulation of mitochondrial biogenesis in skeletal muscle by CaMK. Science 2002, 296:349-352.
43. Patti ME, Butte AJ, Crunkhorn S, et al.: Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1. Proc Natl Acad Sci U S A 2003, 100:8466-8471.
44. Mikines KJ, Sonne B, Farrell PA, et al.: Effect of physical exercise on sensitivity and responsiveness to insulin in humans. Am J Physiol 1988, 254:E248-E259.
45. Perseghin G, Price TB, Petersen KF, et al.: Increased glucose transport-phosphorylation and muscle glycogen synthesis after exercise training in insulin-resistant subjects. N Engl J Med 1996, 335:1357-1362.
46. Knowler WC, Barrett-Connor E, Fowler SE, et al.: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
47. Henry RR, Scheaffer L, Olefsky JM: Glycemic effects of intensive caloric restriction and isocaloric refeeding in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1985, 61:917-925.
48. Petersen KF, Dufour S, Befroy D, et al.: Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance and hyperglycemia by moderate weight reduction in patients with type 2 diabetes mellitus. Diabetes 2005, 54:603-608.
49. Jeng CY, Sheu WH, Fuh MM, et al.: Relationship between hepatic glucose production and fasting plasma glucose concentration in patients with NIDDM. Diabetes 1994, 43:1440-1444.
50. Maggs DG, Buchanan TA, Burant CF, et al.: Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998, 128:176-185.
51. Magnusson I, Rothman DL, Katz LD, et al.: Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. J Clin Invest 1992, 90:1323-1327.
52. Hundal RS, Krssak M, Dufour S, et al.: Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000, 49:2063-2069.
53. Landau BR, Wahren J, Chandramouli V, et al.: Contributions of gluconeogenesis to glucose production in the fasted state. J Clin Invest 1996, 98:378-385.
54. Petersen KF, Krssak M, Navarro V, et al.: Contributions of net hepatic glycogenolysis and gluconeogenesis to glucose production in cirrhosis. Am J Physiol 1999, 276:E529-E535.
55. Mayerson AB, Hundal RS, Dufour S, et al.: The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002, 51:797-802.